Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Genentech, Inc. v. Biogen MA, Inc.
Case Number:
3:23-cv-00909
See also:
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 15, 2025
Biogen, Genentech Head To June Trial Over MS Drug Royalties
A California federal judge on Tuesday denied Biogen's bid for summary judgment in a high-stakes contract fight with Roche Holding AG subsidiary Genentech over patent royalties on multiple sclerosis drug sales, saying during a hearing that there's a material dispute over the contract's language and the case will be tried in June.
-
March 01, 2023
Biogen Owes Patent Royalties For MS Drug, Genentech Says
Biogen Inc. has broken a licensing agreement with Roche Holding AG subsidiary Genentech Inc. by refusing to pay any more royalties from sales of its immunosuppressive drug Tysabri for the treatment of multiple sclerosis and Crohn's disease, according to a lawsuit filed Tuesday in California federal court.